Antimicrobial Use Guidelines (AMUG) version 21 - UW Health

K. References1.0 Bliziotis IA, Plessa E, Pappas G, Falagas ME. Daptomycin versus other antimicrobialagents for the treatment of skin and soft tissue infections: A meta-analysis. AnnalsPharmacother 2010;44:97-106.2.0 Fowler VG, Boucher HW, Corey RG, Abrutyn E, Karchmer AW, Rupp ME, Levine DP,Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M,Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M,Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia StudyGroup. Daptomycin vs. standard therapy for bacteremia and endocarditis caused byStaphylococcus aureus. N Engl J Med 2006;355 653-653.0 Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment ofenterococcal bacteraemia: results from the Cubicin ® Outcomes Registry and Experience(CORE). Int J Antimicrob Agents 2009;33:543-548.4.0 Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG. Cost-effectiveness of daptomycinversus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcusaureus bacteremia or endocarditis. Clin Infect Dis 2009;49:691-698.5.0 Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and theprobability of elevations in the creatine phosphokinase level: Data from a randomized trial ofpatients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-1574.6.0 Salama NN, Segal JH, Churchwell MD, et al. Single-dose daptomycin pharmacokinetics inchronic haemodialysis patients. Nephrol Dial Transplant 2010;25:1279-1284.7.0 Salama NN, Segal JH, Churchwell MD, et al. Intradialytic administration of daptomycin inend stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol. 2009;4:1190-1194.8.0 Vilay AM, Brio M, DePestel DD, et al. Daptomycin pharmacokinetics in critically ill patientsreceiving continous venovenous hemodialysis. Crit Care Med. 2011;39:19-25.